Evidence map›Paper›PMID 27789936›Full record

ReviewClinical ophthalmology (Auckland, N.Z.)2016

Management of noninfectious posterior uveitis with intravitreal drug therapy.

Hui Yi Tan, Aniruddha Agarwal, Cecilia S Lee, Jay Chhablani, Vishali Gupta, Manoj Khatri, Jayabalan Nirmal, Carlos Pavesio, Rupesh Agrawal

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical ophthalmology (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05542381 (The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05542381 nacompletednot on this mapstarted 2022, after this paper: background citation

The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

TypeinterventionalSponsorVirginia Polytechnic Institute and State UniversityRan2022 to 2025Enrolled64ConditionsAge-Related Macular DegenerationArmsLoteprednol Etabonate Ophthalmic Gel [Lotemax], Refresh Lubricant Eye Drops [Artificial Tears]
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Pathogenesis and current therapies for non-infectious uveitis.Clinical and experimental medicine · 2023
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Intraocular therapy in noninfectious uveitis.Journal of ophthalmic inflammation and infection · 2021
    Review
  9. Review
  10. In vitro release of hydrophobic drugs by oleogel rods with biocompatible gelators.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2020
    Article
  11. Article
  12. Review
  13. Management of chronic ocular sarcoidosis: challenges and solutions.Clinical ophthalmology (Auckland, N.Z.) · 2018
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 4 countries.

Hui Yi TanYong Loo Lin School of Medicine, National University of Singapore, Singapore.
Aniruddha AgarwalDepartment of Vitreoretina, Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE.
Cecilia S LeeDepartment of Ophthalmology, University of Washington, Seattle, WA, USA.
Jay ChhablaniDepartment of Vitreoretina, L V Prasad Eye Institute, Hyderabad, Telangana.
Vishali GuptaDepartment of Retina and Uvea, Post Graduate Institute of Medical Education and Research, Chandigarh.
Manoj KhatriDepartment of Retina, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India.
Jayabalan NirmalSchool of Material Science and Engineering, Nanyang Technological University, Singapore.
Carlos PavesioDepartment of Medical Retina, Moorfields Eye Hospital, NHS Foundation Trust, London, UK.
Rupesh AgrawalYong Loo Lin School of Medicine, National University of Singapore, Singapore; School of Material Science and Engineering, Nanyang Technological University, Singapore; Department of Medical Retina, Moorfields Eye Hospital, NHS Foundation Trust, London, UK; Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.
Nanyang Technological University · SGL V Prasad Eye Institute · INMoorfields Eye Hospital NHS Foundation Trust · GBNational University of Singapore · SGPost Graduate Institute of Medical Education and Research · INUniversity of Nebraska Medical Center · USUniversity of Washington · USVasan Eye Care Hospital · IN

Funding

The ocular surface microbiome in potentially infectious ophthalmic diseaseK23EY024921 · NEI · UNIVERSITY OF WASHINGTON · PI LEE, CECILIA SUNGMIN · 2015 to 2019
$991k
NEI NIH HHS K23 EY024921
6 · The paper itself

Abstract

Uveitis is an important cause of vision loss worldwide due to its sight-threatening complications, especially cystoid macular edema, as well as choroidal neovascularization, macular ischemia, cataract, and glaucoma. Systemic corticosteroids are the mainstay of therapy for noninfectious posterior uveitis; however, various systemic side effects can occur. Intravitreal medication achieves a therapeutic level in the vitreous while minimizing systemic complications and is thus used as an exciting alternative. Corticosteroids, antivascular endothelial growth factors, immunomodulators such as methotrexate and sirolimus, and nonsteroidal anti-inflammatory drugs are currently available for intravitreal therapy. This article reviews the existing literature for efficacy and safety of these various options for intravitreal drug therapy for the management of noninfectious uveitis (mainly intermediate, posterior, and panuveitis).

Indexed as

intravitreal methotrexateintravitreal steroidsintravitreal therapynoninfectious uveitisposterior uveitis

Identifiers

PMID27789936
PMCPMC5068474
OpenAlexW2531185339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.